医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ascend Performance Materials Announces Global Price Increase for All Vydyne® Brand Polymers, Fibers and Compounds

2020年10月01日 PM11:00
このエントリーをはてなブックマークに追加


 

HOUSTON

Ascend Performance Materials announced today a global price increase for all of its Vydyne® polymers, fibers and compounds.

The price increase takes effect October 15, 2020, and includes the following price changes:

Materials

Geography

Price Increases

Terms

Vydyne® (PA 66) polymers, fibers and compounds

North America

$220/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Vydyne® (PA 66) polymers, fibers and compounds

Asia

$300/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Vydyne® (PA 66) polymers, fibers and compounds

Europe

€200/MT

  • As contracts allow
  • Non-contract business – price determined on an order-by-order basis

Customers should contact their local sales representative for additional information.

About Ascend Performance Materials

Ascend Performance Materials makes high-performance materials for everyday essentials and new technologies. Our focus is on improving quality of life and inspiring a better tomorrow through innovation. Based in Houston, Texas, and with regional offices in Shanghai, Brussels and Detroit, we are a fully integrated material solutions provider with eight global manufacturing facilities in the United States, Europe and China. Our 2,600-person global workforce makes the plastics, fabrics, fibers and chemicals used to make safer vehicles, cleaner energy, better medical devices, smarter appliances and longer-lasting apparel and consumer goods. We are committed to safety, sustainability and the success of our customers and our communities.

Find out more about Ascend at www.ascendmaterials.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005292/en/

CONTACT

Alison Jahn at +1 713-210-9809, ajahn@ascendmaterials.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続